| Literature DB >> 22471395 |
Judith Matz1, Daniela L Krause, Sandra Dehning, Michael Riedel, Rudolf Gruber, Markus J Schwarz, Norbert Müller.
Abstract
BACKGROUND: Infections and immunological processes are likely to be involved in the pathogenesis of Tourette's syndrome (TS). To determine possible common underlying immunological mechanisms, we focused on innate immunity and studied markers of inflammation, monocytes, and monocyte-derived cytokines.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22471395 PMCID: PMC3356225 DOI: 10.1186/1471-244X-12-29
Source DB: PubMed Journal: BMC Psychiatry ISSN: 1471-244X Impact factor: 3.630
Demographic features and clinical characteristics of TS patients and healthy controls
| Age, mean ± SD (range) | ||||
| < 18 years, n (%) | ||||
| Age of onset, mean ± SD (range) | ||||
| Male:female ratio (n) | ||||
| TSGS values, mean ± SD (range) | ||||
| OCD, n (%), MOCI ≥12, | ||||
| No OCD n (%), MOCI < 12 | ||||
| Psychotropic medication1, n (%) | ||||
| Not medicated |
TS = Tourette’s syndrome, OCD = obsessive compulsive disorder, MOCI = Maudsley Obsessive-Compulsive Inventory, TSGS = Tourette’s Syndrome Global Scale, n = number, f = female, m = male, SD = standard deviation, n.a. = not applicable.
1including neuroleptics (n = 18), tiapride (n = 11) and antidepressants (n = 7).
Concentrations of immune parameters and monocyte markers in TS and healthy controls
| Mean ± SD | |||||
|---|---|---|---|---|---|
| Patients | 0.57 ± 0.22 | 50.1 | −2.152 | 0.031 | |
| | Controls | 0.47 ± 0.11 | 38.37 | | |
| Patients | 0.43 ± 0.18 | 33.09 | −2.421 | 0.015 | |
| | Controls | 0.56 ± 0.25 | 45.39 | | |
| Patients | 1.89 ± 1.71 | 39.41 | −1.215 | n.s. | |
| | Controls | 1,74 ± 1,64 | 33.43 | | |
| Patients | 0.03 ± 0.09 | 36.11 | −2.813 | 0.005 | |
| | Controls | 0.04 ± 0.06 | 51.24 | | |
| Patients | 6.37 ± 1.43 | 30.25 | −4.934 | <0.0001 | |
| | Controls | 8.40 ± 2.00 | 56,68 | | |
| Patients | 0.43 ± 0.27 | 45.53 | −2.013 | 0.044 | |
| | Controls | 0.37 ± 0.37 | 37.85 | | |
| Patients | 6.03 ± 2.19 | 48.51 | −2.084 | 0.037 | |
| Controls | 5.19 ± 1.84 | 37.36 |
SD = standard deviation, n.s. = not significant; *Mann–Whitney U Test.
Analysis of TNF-alpha, sCD14, IL1-ra, and neopterin in co-morbid OCD subgroups
| | | ||||
|---|---|---|---|---|---|
| mean ± SD | 0.52 ± 0.17 | 6.9 ± 1.3 | 0.013 ± 0.014 | 5.10 ± 1.28 | |
| rank sum | 18.82 | 21.05 | 22.25 | 16.50 | |
| mean ± SD | 0.40 ± 0.18 | 6.3 ± 1.4 | 0.034 ± 0.095 | 6.36 ± 2.15 | |
| | rank sum | 26.28 | 26.38 | 22.59 | 24.13 |
| | p-value* (n) | n.s. (9/31) | n.s. (12/32) | n.s. (12/32) | n.s. (12/31) |
| mean ± SD | 0.55 ± 0.24 | 8.4 ± 2,0 | 0.041 ± 0.057 | 5.16 ± 1.75 | |
| rank sum | 40.49 | 47.67 | 42.73 | 31.69 | |
| | mean ± SD | 0.40 ± 0.18 | 6.3 ± 1.4 | 0.034 ± 0.095 | 6.36 ± 2.15 |
| | rank sum | 27.35 | 23.33 | 30.64 | 44.19 |
| | p-value* (n) | ||||
| mean ± SD | 0.55 ± 0.24 | 8.4 ± 2.0 | 0.041 ± 0.057 | 5.16 ± 1.75 | |
| rank sum | 23.91 | 30.01 | 30.01 | 27.17 | |
| | mean ± SD | 0.52 ± 0.17 | 6.9 ± 1.3 | 0.013 ± 0.014 | 5.10 ± 1.28 |
| | rank sum | 21.83 | 16.71 | 18.71 | 28.67 |
| p-value* (n) | n.s. (37/9) | n.s. (42/12) |
TS = Tourette’s syndrome, OCD = obsessive compulsive disorder, n = number, SD = standard deviation, n.s. = not significant, *Mann–Whitney U Test.
Analysis of TNF-alpha, sCD14, IL1-ra, and neopterin in age subgroups
| | | ||||
|---|---|---|---|---|---|
| mean ± SD | 0.67 ± 0.24 | 0.056 ± 0.051 | 8.0 ± 1.4 | 4.70 ± 1.09 | |
| rank sum | 24.00 | 29.45 | 18.89 | 18.80 | |
| mean ± SD | 0.51 ± 0.23 | 0.035 ± 0.058 | 8.6 ± 2.1 | 5.31 ± 1.90 | |
| rank sum | 17.15 | 19.02 | 21.59 | 22.34 | |
| | p-value* (n) | n.s. (10/27) | n.s. (9/32) | n.s. (10/32) | |
| mean ± SD | 0.46 ± 0.20 | 0.056 ± 0.136 | 6.3 ± 1.0 | 5.35 ± 1.79 | |
| rank sum | 22.50 | 25.07 | 20.37 | 17.54 | |
| mean ± SD | 0.41 ± 0.18 | 0.014 ± 0.096 | 6.6 ± 1.6 | 6.32 ± 2.07 | |
| | rank sum | 19.42 | 21.17 | 23.60 | 24.16 |
| | p-value* (n) | n.s. (14/26) | n.s. (15/29) | n.s. (15/29) | n.s. (14/29) |
| mean ± SD | 0.67 ± 0.24 | 0.056 ± 0.051 | 8.0 ± 1.4 | 4.70 ± 1.09 | |
| rank sum | 16.00 | 17.05 | 17.72 | 11.25 | |
| mean ± SD | 0.46 ± 0.20 | 0.056 ± 0.136 | 6.3 ± 1.0 | 5.35 ± 1.79 | |
| | rank sum | 10.00 | 10.30 | 9.37 | 13.39 |
| | p-value* (n) | n.s. (10/14) | |||
| mean ± SD | 0.51 ± 0.23 | 0.035 ± 0.058 | 8.6 ± 2.1 | 5.31 ± 1.90 | |
| rank sum | 30.54 | 35.48 | 39.48 | 26.20 | |
| mean ± SD | 0.41 ± 0.18 | 0.014 ± 0.096 | 6.6 ± 1.6 | 6.32 ± 2.07 | |
| | rank sum | 23.33 | 26.05 | 21.64 | 36.29 |
| p-value* (n) | n.s. (27/26) |
TS = Tourette’s syndrome, n = number, SD = standard deviation, n.s. = not significant, *Mann–Whitney U Test.